3 Dividend Stocks Worth Buying Now?
Thanks to surging stock prices over the past two years, dividend yields on major stock indices have fallen to fairly low levels. The S&P 500, for instance, currently carries an average yield of just 1.3%.
The mature companies in the Dow Jones Industrial Average fare a bit better, and some of them offer yields that exceed the S&P 500 several times over. » Read more about: 3 Dividend Stocks Worth Buying Now? »
Read More
Alert: 43.7% Upside in POT Stock (No, Not That Pot)
Investment Alert: Buy Mosaic (MOS) Under $37/share
Disclaimer: Investment Alerts have a medium to long-term time horizon. These do not constitute financial advice and you should contact a financial advisor before deciding whether it is appropriate for your individual circumstances.
We found a pot stock with lots of upside,
» Read more about: Alert: 43.7% Upside in POT Stock (No, Not That Pot) »
Read More
Alert: 1 Stock That Is Too Damn Cheap To Ignore
Investment Alert: Buy DAVA Under $48/share
Disclaimer: Investment Alerts have a medium to long-term time horizon. These do not constitute financial advice and you should contact a financial advisor before deciding whether it is appropriate for your individual circumstances.
Jimmy McMillan sprung to fame a decade ago as the founder of the “Rent is Too Damn High”
» Read more about: Alert: 1 Stock That Is Too Damn Cheap To Ignore »
Read More
Market Commenary: Did Apple Silently Launch a Brain Machine Interface?
Ten years ago if you told someone that a brain-machine interface would connect humans to machines you would have been at risk of earning a tin foil hat and being labeled a conspiracy theorist.
Read More
Massive Upside In Big Money Pharma Favorite?
Iovance Biotherapeutics (NASDAQ:IOVA) is a fledgling pharmaceutical company that specializes in the use of immune therapies for cancer treatment. Specifically, Iovance is exploring new applications of tumor infiltrating lymphocyte (TIL) therapy, utilizing cells that the human body naturally produces to attack cancerous tumors.
There was lots of hype about this next-generation cancer treatment company but its share price has been decidedly lackluster this year,
» Read more about: Massive Upside In Big Money Pharma Favorite? »
Read MoreThe Ivy
The Danger Is Still High, Here’s Why
After a face-ripping rally Wednesday, markets took a breather yesterday. Futures were pointing lower, which, frankly, wasn’t all that surprising given how sharply things ripped higher.
But while some have pointed to a bottom, the reality is the danger is still high. Look no further than how the rally failed at the downtrending resistance line.
» Read more about: The Danger Is Still High, Here’s Why »
Read MoreThe Spotlight
Will This $20 Million Bet Pay Off?
A report just came out that one trader bet a massive $20 million on a single stock rising by 30% on its next earnings report. That stock is, drumroll, artificial intelligence favorite, Nvidia.
The bet was made by purchasing strike 1180 call options on Nvidia for the June expiration, meaning if NVDA share price rise were to rise above that level on expiration day,
» Read more about: Will This $20 Million Bet Pay Off? »
Read MoreThe Daily
Proliferation of ETFs May Squeeze Balance Sheets
Moves by the U.S. Securities and Exchange Commission in the exchange-traded fund market, which are likely to lead to a proliferation of new products, have led to concerns that the balance sheets of authorized participants may become constrained.
The SEC has allowed Dimensional Fund Advisors to launch an ETF share class of an existing mutual fund,
» Read more about: Proliferation of ETFs May Squeeze Balance Sheets »